effector and memory T cell generation.
Mutations of the nucleophosmin gene (NPM1) have been described as the single most frequent abnormality in adult patients with acute myeloid leukemia (reviewed in Falini et al. 1 ). These mutations cluster in exon 12, coding for the COOHterminal region of NPM1 and always induce a net insertion of four bases. The consecutive frameshift results in an elongated protein which contains an additional nuclear export signal and leads to an abnormal cytoplasmic localization of the protein. 2 The most common type of mutation (type A), the duplication of the four bases TCTG, is found in approximatley 80% of all adult cases, but more than 40 additional mutations have been described. 2, 3 In adult AML, NPM1 mutations were found to be associated with a distinct subgroup of patients with particular clinical (female sex, high WBC counts), morphological (cup-like morphology, lack of CD34 expression) and cytogenetic (normal karyotype) characteristics. 1 In addition, several studies in adults have shown that NPM1-mutations represent an independent good prognostic marker, but only if not associated with FLT3-ITD mutations.
1 Few data exist on the incidence and relevance of NPM1-mutations in children. The study by Cazzaniga et al. 4 is the only report specifically investigating NPM1-mutations in pediatric AML. They found a low overall prevalence of 6.5% (7/107 patients), and showed that cases with NPM1 mutation were older and frequently had a normal karyotype. Only one additional study referred to NPM1-mutations in children, but did not further specify the pediatric patients. 5 To gain further insight in the role of NPM1 in pediatric AML, we have investigated NPM1 mutations in a cohort of 75 children and young adults with AML (including one patient borderline to advanced MDS) treated in the AML98 and AML2004 protocols of the Berlin-Mü nster-Frankfurt (BFM) study group. 6 DNA was extracted from cryopreserved cells and screened for NPM1 and FLT3 mutations using high resolution fragment analysis. 7 Overall, 9/75 (12%) samples showed NPM1-mutations. As reported in adults, 1 children with NPM1-mutations predominantly had a normal karyotype (NPM1-mut: 8/9; 89% compared to NPM1-wt: 30/56; 54%; P ¼ 0.069). Patients with NPM1 mutations were older (median age 13.2 vs 10.4 years) and -as shown in adultspredominantly had female sex (56 vs 33%). They frequently also showed an FLT3-ITD mutation (44 vs 23%), but due to the small number of cases, none of these associations was significant. Interestingly, all patients with NPM1 mutations are alive in remission (except one, who died before starting treatment from cerebral bleeding), irrespective of the FLT3-ITD status, but this has clearly to be interpreted with caution, due to the small number of patients.
We also sequenced all positive cases. Interestingly, only one of the patients had mutation A, the predominant variant in adults. The most common mutation in this pediatric group was type B (6/9; 67%; Table 1 ). As Cazzaniga et al. 4 also found only 1/7 cases with mutation A, we asked whether this distribution was by chance and compared the mutational spectrum of 434 recently analyzed adult patients with NPM1-mutations with the pediatric cases. The comparison of type A mutations (323/434 adults and 1/9 children) and non-type A mutations (111/434 adults and 8/9 children) showed a highly significant difference in the prevalence of this alteration (P ¼ 0.0002; Fisher's exact test). A comparison of the age of the adult patients with type A and non-type A mutations indicated that patients with type A mutations had a trend for a higher median age (60 years), compared to cases with non-A mutations (median age 57 years; P ¼ 0.068). When analyzed in age groups (below and above 50 years), the non-type A mutation frequency was 32% below the age of 50 and only 23% above this age (P ¼ 0.015). Abbreviations: allo SCT, allogeneic stem cell transplantation, F, female; M, male; MDS, myelodysplastic syndrome; Neg., negative; Pos., positive. a This patient was borderline to MDS-RAEB (20% blasts in the bone marrow).
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Taken together, the data reported by Cazzaniga et al. and our results consistently show that in pediatric patients, NPM1 mutations are less common than in adults and tend to affect older patients. Preliminary data also indicate that NPM1 mutations might be associated with favorable outcome, which warrants further studies to address this question. In addition, our results point to an effect of age on the prevalence of different NPM1-mutations, with non-typical (i.e. non-type A) mutations being most prevalent in children and younger adults. The reason for this association is unknown, but might refer to different molecular mechanisms involved in the development of this abnormality, a process which is currently largely unclear. This finding has also important implications for the MRD analysis and molecular follow-up of pediatric cases with NPM1 þ AML. Whereas in adults, type A mutations predominate and assays focusing on this type will be suitable in most cases, in pediatric patients mutations should always be analyzed by sequencing. In these cases, a recently reported LNA-based procedure might be advantageous for follow-up of residual disease after treatment. Juvenile myelomonocytic leukemia (JMML) is a unique clonal myelodysplastic/myeloproliferative disorder of infancy and early childhood, characterized by an aggressive clinical course and an extremely poor prognosis for patients who cannot receive an allogeneic hematopoietic stem cell transplantation.
1,2 The disease, usually presenting with leukocytosis and monocytosis, anemia, thrombocytopenia, hepatomegaly and marked splenomegaly, is characterized by an uncontrolled proliferation of monocytic lineage cells. Spontaneous growth of monocytemacrophage colonies in semisolid media cultures in the absence of added growth factors, as well as a striking hypersensitivity of JMML myeloid progenitors to granulocyte-macrophage colonystimulating factor (GM-CSF), is a distinctive feature of the disease. 1 A pathologic activation of the RAS-RAF-MAP (mitogenactivated protein) kinase signal-transduction pathway from GM-CSF receptor to the nucleus is the key point of the pathophysiology of this disease. 3, 4 In about 70% of JMML cases, this activation is due to mutations in RAS (25% of cases), NF1 (clinical diagnosis in about 11% of cases) or PTPN11 (35% of cases). [3] [4] [5] All these genetic aberrations have been demonstrated to be able to produce, in experimental models, the development of progressive myeloproliferative disorders. 4, 6 However, even though one of these gene mutations can be observed in more than two-thirds of JMML patients, in the remaining affected children a specific genetic alteration has not been identified so far. Janus kinase 2 (JAK2) is one of the four tyrosine kinases involved in the transduction of cellular growth stimuli. After activation of growth factor or cytokine receptors, JAK proteins are recruited and activated through trans-phosphorylation. Following activation, JAK proteins phosphorylate specific tyrosine residues on the receptor, which then bind to signal transducer and activator of transcription (STAT) proteins, which further activate downstream signaling events. A somatic activating mutation, 1849G4T, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F) was recently described in patients with myeloproliferative syndromes, such as polycythemia vera (PV) and essential thrombocythemia. 7 More recently, the V617F mutation was observed also in other acute and chronic myeloid malignancies (acute myeloid leukemia and chronic myelomonocytic leukemia (CMML)). 8 We investigated a possible role of V617F mutation of JAK2 in the development of JMML, especially in the subgroup of patients with unknown genetic defects.
Sixty-two children with a diagnosis of JMML were enrolled in the present study. Thirty-nine were boys and 23 girls. The median age at diagnosis was 1.3 years, with a range from 0.2-9 years. Details on the clinical characteristics at disease presentation are reported in Table 1 . Three additional patients with a diagnosis of CMML were evaluated and included in the present study. CMML was secondary after chemotherapy for neuroblastoma or acute promyelocytic leukemia in a 3-and a 14-year-old patient, and primary in an 18-year-old boy. All patients included in the study had been reported to the
